¡Desconecta con la aplicación Player FM !
Highlights from ASH: Canadian Perspective on the ALPINE Trial in CLL
Manage episode 350189121 series 2812899
Live From ASH, New Orleans:
In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans.
Our Guest:
Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode, Dr. Sehn discusses the impact of the results of the ALPINE trial for clinical practice in Canada given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 episodios
Manage episode 350189121 series 2812899
Live From ASH, New Orleans:
In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans.
Our Guest:
Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode, Dr. Sehn discusses the impact of the results of the ALPINE trial for clinical practice in Canada given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 episodios
Усі епізоди
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.